How COVID-19 pandemic changed our attitude to venetoclax-based treatment in chronic lymphocytic leukemia

Marina Deodato; Anna Maria Frustaci; Paolo Sportoletti; Luca Laurenti; Roberta Murru; Andrea Visentin; Gianluigi Reda; Francesca Romana Mauro; Giulia Quaresmini; Anna Vanazzi; Candida Vitale; Lorella Orsucci; Massimo Massaia; Alessandro Sanna; Marina Motta; Adalberto Ibatici; Isacco Ferrarini; Chiara Borella; Marzia Varettoni; Monica Tani; Sara Marinoni; Andrea Ferrario; Giulia Zamprogna; Marco Montillo; Alessandra Tedeschi

doi:10.1080/10428194.2022.2053532

How COVID-19 pandemic changed our attitude to venetoclax-based treatment in chronic lymphocytic leukemia

Leuk Lymphoma. 2022 Aug;63(8):1985-1988. doi: 10.1080/10428194.2022.2053532. Epub 2022 Mar 27.

Authors

Marina Deodato¹, Anna Maria Frustaci¹, Paolo Sportoletti², Luca Laurenti³, Roberta Murru⁴, Andrea Visentin⁵, Gianluigi Reda⁶, Francesca Romana Mauro⁷, Giulia Quaresmini⁸, Anna Vanazzi⁹, Candida Vitale¹⁰, Lorella Orsucci¹¹, Massimo Massaia¹², Alessandro Sanna¹³, Marina Motta¹⁴, Adalberto Ibatici¹⁵, Isacco Ferrarini¹⁶, Chiara Borella¹⁷, Marzia Varettoni¹⁸, Monica Tani¹⁹, Sara Marinoni²⁰, Andrea Ferrario²¹, Giulia Zamprogna¹, Marco Montillo¹, Alessandra Tedeschi¹

Affiliations

¹ Department of Hematology, Niguarda Cancer Center, ASST Grande Ospedale Metropolitano Niguarda, Milano, Italy.
² Department of Medicine and Surgery, Institute of Hematology, Centro di Ricerca Emato-Oncologica (CREO), University of Perugia, Perugia, Italy.
³ Institute of Hematology, Fondazione Policlinico Universitario A. Gemelli IRCCS, Roma, Italy.
⁴ Hematology and Stem Cell Transplantation Unit, Ospedale Oncologico A. Businco, Cagliari, Italy.
⁵ Department of Medicine, Hematology and Clinical Immunology Unit, University of Padova, Padova, Italy.
⁶ U.O.C. Ematologia, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico di Milano, Milano, Italy.
⁷ Hematology, Department of Translational and Precision Medicine, 'Sapienza' University, Roma, Italy.
⁸ USC Ematologia, ASST PAPA GIOVANNI XXIII, Bergamo, Italy.
⁹ Division of Clinical Haemato-Oncology, IEO, European Institute of Oncology IRCCS, Milan, Italy.
¹⁰ Division of Hematology, A.O.U. Città della Salute e della Scienza di Torino and Department of Molecular Biotechnology and Health Sciences, Università di Torino, Torino, Italy.
¹¹ S.C. Ematologia, AOU Città della Salute e della Scienza, Torino, Italy.
¹² Hematology Unit, ASO Santa Croce e Carle, Cuneo, Italy.
¹³ Hematology, Department of Oncology, AOU Careggi, Florence, Italy.
¹⁴ Hematology Department, ASST Spedali Civili, Brescia, Italy.
¹⁵ Hematology Unit and Bone Marrow Transplantation, IRCCS Ospedale Policlinico San Martino, Genova, Italy.
¹⁶ Department of Medicine, Section of Hematology, University of Verona, Verona, Italy.
¹⁷ Hematology Department, San Gerardo Hospital, ASST Monza, Monza, Italy.
¹⁸ Division of Hematology, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy.
¹⁹ U.O.C. di Ematologia Ospedale Santa Maria delle Croci, Ravenna, Italy.
²⁰ UOC Ematologia, ASST Ovest milanese, Ospedale di Legnano, Legnano, Italy.
²¹ UO Ematologia, ASST Sette Laghi, Ospedale di Circolo, Varese, Italy.

PMID: 35343363
DOI: 10.1080/10428194.2022.2053532

No abstract available

Keywords: COVID-19; Chronic lymphocytic leukemia; Rituximab; venetoclax.

Publication types

Letter

MeSH terms

Antineoplastic Combined Chemotherapy Protocols / adverse effects
Bridged Bicyclo Compounds, Heterocyclic / adverse effects
COVID-19*
Humans
Leukemia, Lymphocytic, Chronic, B-Cell* / drug therapy
Pandemics
Sulfonamides

Substances

Bridged Bicyclo Compounds, Heterocyclic
Sulfonamides
venetoclax